Home
Rebecca Jane  Cox Brokstad's picture

Rebecca Jane Cox Brokstad

Professor, Head of the Influenza Centre
  • E-mailRebecca.Cox@uib.no
  • Phone+47 55 97 46 68+47 452 42 974
  • Visitor Address
    5th Floor Laboratory Building
    Jonas Leis vei 87
    5021 Bergen
    Room 
    Office address: Room 114 Armauer Hansens Hus
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2020. Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
  • 2020. Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases.
  • 2020. Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.
  • 2019. Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia. Nutrients. 1-14.
  • 2019. No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine: X. 1-8.
  • 2019. Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Influenza and Other Respiratory Viruses. 1-7.
  • 2019. Low temperature and low UV indexes correlated with peaks of influenza virus activity in Northern Europe during 2010-2018. Viruses. 1-10.
  • 2019. Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
  • 2019. Common nodes of virus-host interaction revealed through an integrated network analysis. Frontiers in Immunology. 12 pages.
  • 2018. T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome. Scandinavian Journal of Immunology. 1-15.
  • 2018. Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research. 174-182.
  • 2018. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. Vaccine. 2213-2219.
  • 2018. Impact of erythrocyte species on assays for influenza serology. Journal of Preventive Medicine and Hygiene (JPMH). E1-E7.
  • 2018. Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines. 10 pages.
  • 2018. Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-year follow-up study. Clinical Infectious Diseases. 382-392.
  • 2018. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.
  • 2018. Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness. Influenza and Other Respiratory Viruses. 191-200.
  • 2017. Mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza H5N1 in mice. Frontiers in Immunology. 1-15.
  • 2017. Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. mBio. 1-13.
  • 2017. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
  • 2017. High prevalence of humoral and cellular immunity to influenza viruses in preschool children living in Addis Ababa, Ethiopia. Open Forum Infectious Diseases. 6 pages.
  • 2017. Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy. PLOS ONE. 14 pages.
  • 2017. Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
  • 2017. A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. Journal of Virology. 1-13.
  • 2016. Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients. Respiratory Medicine. 53-59.
  • 2016. Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction. Mucosal Immunology. 884-893.
  • 2016. Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection: a morphologic and molecular genetic study. Influenza and Other Respiratory Viruses. 525-531.
  • 2016. Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. Journal of Infectious Diseases. 740-749.
  • 2016. Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
  • 2016. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Vaccine. 3576-3583.
  • 2016. Epitope specific T-cell responses against influenza A in a healthy population. Immunology. 165-177.
  • 2016. Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination. npj Vaccines.
  • 2016. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine. 191-198.
  • 2015. Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses. JIM - Journal of Immunological Methods. 95-101.
  • 2015. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio. 13 pages.
  • 2015. The expression of B & T cell activation markers in children’s tonsils following live attenuated influenza vaccine. Human Vaccines & Immunotherapeutics. 1663-1672.
  • 2015. Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics. 1654-1662.
  • 2015. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 4146-4154.
  • 2015. Need for more targeted measures - Only less severe hospital-associated infections declined after introduction of an infection control program. Journal of Infection and Public Health. 282-290.
  • 2015. Mortality related to hospital-associated infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrobial Resistance and Infection Control. 1-8.
  • 2015. Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets. PLOS ONE.
  • 2015. Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
  • 2015. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge. Human Vaccines & Immunotherapeutics. 1235-1243.
  • 2015. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines. 373-389.
  • 2015. Induction of local secretory IgA and multifunctional CD4+ T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB/c mice. Scandinavian Journal of Immunology. 305-317.
  • 2015. Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLOS ONE. 16 pages.
  • 2014. The Influence of Tonsillectomy on Total Serum Antibody Levels. Scandinavian Journal of Immunology. 377-379.
  • 2014. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 4550-4557.
  • 2014. Matrix M™ adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man. Human Vaccines & Immunotherapeutics. 2408-2416.
  • 2014. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLOS ONE.
  • 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of Virology. 13260-13268.
  • 2014. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
  • 2014. Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases. 9 pages.
  • 2014. Divergent H7 immunogens offer protection from H7N9 virus challenge. Journal of Virology. 3976-3985.
  • 2014. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clinical and Vaccine Immunology. 1153-1163.
  • 2012. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 90-100.
  • 2012. The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics. 653-661.
  • 2012. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. Journal of Infectious Diseases. 158-166.
  • 2012. Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Family Practice. 139-146.
  • 2012. A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. Journal of Infectious Diseases. 1660-1669.
  • 2011. Pandemic influenza vaccination of hypogammaglobulinemic patients induces normal or elevated influenza-specific CD4+Th1-cell responses. Influenza and Other Respiratory Viruses. 376-379.
  • 2011. Pandemic Influenza Vaccination Elicits Influenza-Specific CD4(+) Th1-cell Responses in Hypogammaglobulinaemic Patients: Four case reports. Scandinavian Journal of Immunology. 210-218.
  • 2011. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza and Other Respiratory Viruses. 426-437.
  • 2011. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4(+) cells and strong mucosal and systemic antibody responses in mice. Vaccine. 4973-4982.
  • 2011. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLOS ONE. 12 pages.
  • 2011. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M (TM) adjuvant in a phase I clinical trial. Vaccine. 8049-8059.
  • 2010. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 266-273.
  • 2009. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 7367-7376.
  • 2009. A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza and Other Respiratory Viruses. 21-28.
  • 2009. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 1889-1897.
  • 2009. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza and Other Respiratory Viruses. 107-117.
  • 2007. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clinical and Laboratory Immunology. 978-983.
  • 2007. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scandinavian Journal of Immunology. 14-21.
  • 2006. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 6585-6587.
  • 2006. The humoral and cellular responses induced locally and systematically after parenteral influenza vaccination in man. Vaccine. 6577-6580.
  • 2006. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scandinavian Journal of Immunology. 467-475.
  • 2005. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian Journal of Immunology. 36-44.
  • 2005. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scandinavian Journal of Immunology. 342-352.
  • 2002. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. Journal of Infectious Diseases. 878-884.
  • 2002. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
  • 2001. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 4743-4749.
  • 2001. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
  • 2001. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scandinavian Journal of Immunology. 243-247.
Lecture
  • 2018. Vaksinering av helsepersonell hva vet vi?
Popular scientific lecture
  • 2019. Hva er god helse? Når skolemedisin møter vaksinemotstand.
  • 2017. Hvorfor trenger vi fortsatt vaksiner?
  • 2015. Ytringsfrihet.
Academic lecture
  • 2020. Case study: Influenza; impact of pre-existing immunity on study end points .
  • 2019. Immune responses to influenza A/H1N1pdm09 virus after adjuvanted pandemic and seasonal influenza vaccination in healthcare workers.
  • 2019. Critical Nodes of Viral Modulation Revealed Through an Integrated Network Analysis of Host-Virus Interaction Landscape.
  • 2018. Using human influenza vaccine studies to define next generation vaccines .
  • 2018. Subject selection and screening for susceptibility to challenge.
  • 2018. Should we vaccinate health care workers against influenza annually?
  • 2018. Should we annually vaccinate health care workers against influenza?
  • 2018. Hvorfor trenger vi fremdeles vaksiner? og Influensa en evig kamp. .
  • 2015. Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
  • 2014. The Norwegian Influenza cohort study (NorFlu): immune responses in H1N1 pdm exposed versus non-exposed pregnant women.
  • 2014. The Norwegian Influenza cohort (NorFlu): immune responses in pdmH1N1 exposed versus non-exposed pregnant women.
  • 2014. Perinatal outcomes and children’s health after prenatal exposure to influenza infection and vaccination.
  • 2005. The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man.
  • 2004. The antibody response to parenteral influenza vaccination � A review of specificity, magnitude, rapidity and shortcomings.
  • 2003. The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • 2003. The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • 2002. Influenzaantigenspecific cells in human nasal mucosa.
  • 2002. Influenza-specific antibody producing cells in human nasal mucosa.
  • 2002. Influenza-specific antibody producing cells in human nasal mucosa.
  • 2002. Influenza specific antibodysecreting cells in nasal mucosa, prior to and after vaccination.
  • 2002. Influenza specific antibody secreting cells in nasal mucosa.
  • 2001. The level of influenzaspecific antibodysecreting cells in nasal mucosa, prior to an after vaccination.
  • 2001. The effect of relenza treatment on the early immune response induced after influenza vaccination.
  • 2001. The basal level of influenza specific antibody secreting cells in healthy subjects.
  • 2001. Influenza specific antibody secreting cells (I-ASC)in human nasal mucosa. Relation to tonsil, blood and parenteral vaccination.
  • 2001. Influensaantigenspecifika, antikroppsproducerande lymfocyter i human nasal slemhinne.
  • 2001. DNA vaccination with HA or NP encoding plasmids results in rapid viral clearance after viral challenge.
  • 2001. Antibodies from lymphocytes used as diagnostic markers: A novel approach.
Editorial
  • 2013. Correlates of protection to influenza virus, where do we go from here? Human Vaccines & Immunotherapeutics. 405-408.
  • 2012. The mucosal vaccine quandary Intranasal vs. sublingual immunization against influenza. Human Vaccines & Immunotherapeutics. 690-694.
  • 2006. Pandernic influenza vaccine development: time is of the essence. Expert Review of Vaccines. 603-606.
  • 2006. Pandemic influenza vaccine development: time is of the essence. Expert Review of Vaccines.
Reader opinion piece
  • 2013. A(H1N1)pdm09 Vaccination of Healthcare Workers: Improved Immune Responses in Low Responders Following Revaccination Reply. Journal of Infectious Diseases. 1186-1188.
  • 2011. Lars R. Haaheim PhD (1945-2011) Obituary. Influenza and Other Respiratory Viruses. 297-298.
  • 2009. The Immunogenicity of a Cell-derived H7N1 Split Influenza Virion Vaccine in Mice. Scandinavian Journal of Immunology. 576-578.
Thesis at a second degree level
  • 2004. The humoral immune response after influenza viral challenge of mice previously immunised with inactivated influenza vaccine.
Popular scientific article
  • 2018. Pandemivaksinen i 2009-en forberedelse til neste influensapandemi. Best practices.
Feature article
  • 2018. Få en influensafri jul! Bergens Tidende.
  • 2017. Nok tro og folelser na. Bergens Tidende.
  • 2017. Gravide – se opp for fake news! Bergens Tidende.
  • 2015. Sølje Bergman er farligere for barn enn vaksiner. Bergens Tidende.
Doctoral dissertation
  • 2019. Live Attenuated Influenza Vaccine (LAIV) Immunization in Children and Adults: Lesson for Development of Universal Influenza Vaccine.
  • 2018. Long-term immune response after pandemic and seasonal influenza vaccination in healthcare workers.
  • 2016. Immune response to influenza after vaccination and infection.
Interview
  • 2020. Wuhan-viruset sprer seg. Nå tas det drastiske grep over hele verden.
  • 2020. Treng vi å frykte koronaviruse i noreg.
  • 2020. Professor om coronaviruset: – Ingen grunn til å bekymre seg for covid-19.
  • 2020. Oppfyller kriteriene for sykdom x.
  • 2020. Ni spoersmaal og svar om coronaviruset.
  • 2020. Kinesiske forskere har funnet flere risikofaktorer hos dem som døde.
  • 2020. Hysteri samanlikna med dei gløymde krisene.
  • 2020. Hvor farlig er det nye, kinesiske koronaviruset?
  • 2020. Hva skjer om du blir smittet av coronavirus?
  • 2020. Derfor har ikke sverige strengere krav.
  • 2020. Coronaviruset: Familien til Chen er isolert i Kina.
  • 2020. Bør du unngå å ta buss og er koronaviruset farlig for gravide?
  • 2020. 45 i isolasjon på Landås etter skiferie.
  • 2020. 10 kjappe om coronaviruset.
  • 2019. Dette appa­ratet kan på 15 minutter finne ut om du har influ­ensa.
  • 2018. Man flu. Dette mener ekspertene om «man flu».
  • 2017. Årlege influensavaksiner hindrar ikkje naturleg immunitet.
  • 2017. Årlege influensavaksiner hindrar ikkje naturleg immunitet.
  • 2017. Årlege influensavaksinar hindrar ikkje naturleg immunitet.
  • 2017. Influensasesong.
  • 2017. 3000 prøver gav trygge svar om influensavaksinen .
  • 2014. Behandling med Tamiflu reduserte mortaliteten under Pandemien i 2009.
Documentary
  • 2013. Målet er en livsvarig supervaksine mot influensa.
  • 2013. Forskning på ny influensa vaksine for barn.
Programme participation
  • 2020. Spørsmål og svar om koronaviruset.
Academic chapter/article/Conference paper
  • 2004. The kinetics of the systemic and local immune response to parenteral influenza vaccination. 4 pages.
  • 2004. The immune response to H7N1 whole virus vaccine in mice. 4 pages.
  • 2004. Comparison of the humoral immune response to split and whole virus vaccines in mice. 4 pages.
  • 2003. Detection of antibodies to influenza virus in human mucosal tissues and fluids.
Abstract
  • 2011. Influenza Specific T-Cell Responses Predict Later Neutralizing Antibody Titres in a Phase 1 Clinical Trial of a Virosomal H5N1 Vaccine Adjuvanted with Matrix-M. Scandinavian Journal of Immunology. 355-355.
  • 2011. Comparison of Different Routes of Administration for Influenza Vaccines in a Murine Model. Scandinavian Journal of Immunology. 351-351.
Poster
  • 2019. Seasonal influenza vaccination induces broad antibody responses against antigenically distinct A/H3N2 viruses.
  • 2019. Seasonal Influenza Vaccination Induces Cross-Reactive Antibodies Against A/H3N2 Viruses.
  • 2019. Neuraminidase antibody responses after pandemic and seasonal influenza vaccinations: a five-year study.
  • 2019. Neuraminidase Antibody Responses After Pandemic And Seasonal Vaccination: A Five-Year Study.
  • 2016. The Norwegian Influenza cohort (NorFlu): immune responses in pregnant women during the 2009 H1N1 influenza A pandemic.
  • 2016. Cellular correlates of protection against A(H1N1)pdm09 pandemic influenza during pregnancy.
  • 2014. Perinatal outcomes and children’s health after prenatal exposure to influenza infection and vaccination.
  • 2013. Perinatal outcomes and children’s health after prenatal exposure to influenza infection and vaccination.
  • 2007. Immunisation of mice with whole inactivated avian influenza H7N1 virus vaccine.
  • 2005. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
  • 2005. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
  • 2005. The cytokine and the antibody responses after vaccination with influenza split or whole virus vaccines in mice.
  • 2005. Cytokine profile and lymphocyte pattern influenced by parenteral influenza vaccination.
  • 2004. The humoral immune response in mice after vaccination and subsequent challenge with live influenza virus.
  • 2003. The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • 2003. The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • 2003. The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • 2003. The kinetics of the systemic and local immune response to parenteral influenza vaccination.
  • 2003. The immune response to H7N1 whole virus vaccine in mice.
  • 2003. Local and systemic immune response to inactivated influenza vaccine.
  • 2003. Comparison of the humoral immune response to split and whole virus vaccines in mice.
  • 2002. Influenzaspecific antibodysecreting cells in nasal mucosa, prior to and after vaccination.
  • 2002. Influenzaantigenspecific cells in human nasal mucosa.
  • 2002. Influenza specific antibody secreting cells in nasal mucosa.
Errata
  • 2018. Publisher Correction: Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines.
Academic literature review
  • 2020. Prospects and challenges in the development of universal influenza vaccines. 1-12.
  • 2018. Influensa-alltid relevant . 15-17.
  • 2018. Improving influenza vaccines: challenges to effective implementation. 88-95.
  • 2017. Immune responses after live attenuated influenza vaccination . 571-578.
  • 2009. Pandemic influenza vaccines - the challenges. 1089-1109.
  • 2007. Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. 229-240.
  • 2004. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. 1-15.
Article in business/trade/industry journal
  • 2018. Immunrespons etter levende svekket influensavksine. Best practices.
Interview Journal
  • 2017. 3000 prøver gav trygge svar om influensavaksinen . NRK.

More information in national current research information system (CRIStin)